

Mr Shri Jagat Prakash Nadda
Union Minister
Ministry of Health & Family Welfare
155 - A, Nirman Bhavan
New Delhi - 110108
India

17 October 2016

Dear Minister,

Re: Approval of Measles Rubella Vaccine Support for India

We are writing in relation to India's application to Gavi, the Vaccine Alliance, for Measles Rubella Vaccine (MR) campaign support, which was submitted to the Gavi Secretariat in May 2016.

In line with the provisions stated in the recently signed Annex 6 of the Partnership Framework Agreement (PFA), the application was reviewed in country by an independent expert review team, who made recommendations to the country regarding the proposed implementation plans. Following receipt of satisfactory responses to these recommendations, we are pleased to inform you that **Gavi has approved India's application for MR campaign support**, as per the following Decision Letter.

The Decision Letter states that Gavi will commit \$115 million for MR support, from the total allocation of \$500 million for the period 2016 – 2021, as provided under Annex 6 of the PFA. We anticipate that this commitment will be increased to include the 20 million vaccine doses to be donated by Serum Institute of India to Gavi for the Government of India. We expect that the donation agreement will be signed shortly and we will confirm the additional doses to you in writing.

In calculating the doses available to India, we have used the current price for the MR vaccine, which includes taxes levied on the vaccine (6% excise duty and 5% tax for doses specific to Maharashtra state, one of the states involved in the campaign). We are looking into this further to understand whether there are tax exemptions available for vaccines purchased by UNICEF.

Finally, we note that the Gavi Board's decision to provide catalytic support for India's MR programme is subject to the provisions of Annex 6 of the PFA, in particular the commitments of the Government of India to fund additional costs required as well as scale-up of the programme, and to implement the programme as set out in the approved Performance Framework.



Please do not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,

A handwritten signature in blue ink that reads "Hind Khatib-Othman". The signature is written in a cursive, flowing style.

Hind Khatib-Othman
Managing Director, Country Programmes

Cc:

PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

India Support for Measles Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: India		
2. Grant number: 17-IND-18a-X		
3. Date of Decision Letter: 17 October 2016		
4. Date of the Partnership Framework Agreement: 12 June 2015		
5. Programme title: NVS, Measles Rubella Campaign		
6. Vaccine type: Measles Rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED		
8. Programme duration¹: 2017		
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)		
	2017	Total ²
Programme Budget Gavi (US\$)	US\$115,360,000	US\$115,360,000
10. Vaccine introduction grant (in US\$): Not applicable		
11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement) ³		
Type of supplies to be purchased with Gavi funds in each year	2017 – Gavi Total	
Number of Measles Rubella vaccines doses	176,923,100	
Annual Amounts (US\$)	US\$115,360,000	
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		
15. Operational support for campaigns: Not applicable		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme. The Programme budget comprises \$115 million as committed to India as part of the India Partnership Strategy (adjusted for budget variance) and it is anticipated that this will be increased by \$12 million in respect of donated doses from the manufacturer, following signature of the donation agreement with the manufacturer. This is based on the current price of the vaccine, as well as taxes and freight costs.

³ This is the amount that Gavi has approved.

16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

Reports and other information	Due dates
SIA technical report	Within three months of the finalisation of the campaign
Post campaign coverage survey report and actual expenditures report.	As soon as available
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Gavi's catalytic support for India is subject to the provisions in Annex 6 of the Partnership Framework Agreement, and in particular:

- The commitments of the Government of India to provide financing to fund the additional costs required for each programme that is funded with the Partnership Support and to scale up the programmes; and
- Implementation of the programmes in line with the timelines, milestones and indicators set out in the performance framework.

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
17 October 2016